logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2H 2018
Celsion Corp.
Early clinical findings and translational data from Phase I/II OVATION II Study of GEN-1
Ovarian cancer
2H 2018
Allena Pharmaceuticals, Inc.
Interim data from Phase 2 basket trial of ALLN-177(Study 206 )
Primary Hyperoxaluria or Enteric Hyperoxaluria and Hyperoxalemia
2H 2018
RedHill Biopharma Ltd.
Top-line results from confirmatory Phase 3 study of TALICIA (ERADICATE Hp 2 study)
H. pylori infection
Q3 2018
Palatin Technologies Inc.
Top line data from phase I SAD/MAD study of PL-8177
Ulcerative colitis and other inflammatory bowel diseases
2H 2018
uniQure N.V.
submission of IND for AMT-130
Huntington's disease
2H 2018
Conatus Pharmaceuticals Inc
Top-line results from phase IIb trial of Emricasan (ENCORE-PH)
Liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), and severe portal hypertension
Q3 2018
Ovid Therapeutics Inc.
Topline data from phase 2 study of OV101 (STARS)
Angelman Syndrome
2H 2018
Ovid Therapeutics Inc.
Topline data from Phase 1b/2a trial of TAK-935/OV935
Adults with Rare Developmental and Epileptic Encephalopathies
2H 2018
resTORbio, Inc.
Data from phase IIb trial of RTB101
Respiratory tract infections (RTIs)
2H 2018
CymaBay Therapeutics Inc.
52-week data from phase II study of Seladelpar
Primary Biliary Cholangitis
Q3 2018
Summit Therapeutics plc
48-week data from PhaseOut DMD trial of Ezutromid
Duchenne muscular dystrophy
Q3 2018
Selecta Biosciences Inc.
Data from 5 doses phase II trial of SEL-212
Chronic severe gout
Q3 2018
Pfenex Inc.
Submission of NDA for PF708
Osteoporosis
Q3 2018
Summit Therapeutics plc
Top-line 48-week data from phase II trial of Ezutromid (PhaseOut DMD study)
Duchenne muscular dystrophy
21-May-2018
Eleven Biotherapeutics, Inc.
Topline data from phase III trial of Vicinium (VISTA)
High grade non-muscle invasive bladder cancer
18-May-2018
RXi Pharmaceuticals Corp.
Update on phase II study of Samcyprone
Cutaneous warts
17-May-2018
RXi Pharmaceuticals Corp.
Update on phase II study of RXI-109
Hypertrophic scars
Mid 2018
Audentes Therapeutics, Inc.
Filing of IND for AT982
Pompe Disease
Mid 2018
Aevi Genomic Medicine Inc.
Top line data from phase 2b clinical trial of AEVI-001
Genetic subset of patients with ADHD
Mid 2018
RedHill Biopharma Ltd.
Top-line results from Phase 3 study of RHB-104 (MAP US study)
Crohn’s disease
Mid 2018
Bellerophon Therapeutics LLC
Readout of interim analysis of phase III INOvation-1 study of INOpulse
Pulmonary arterial hypertension
Mid 2018
Arbutus Biopharma Corp.
Submission of IND/CTA-regulatory filing for AB-506
HBV
Mid 2018
Arbutus Biopharma Corp.
Submission of IND/CTA-regulatory filing for AB-452
Chronic HBV
Mid 2018
KEMPHARM, INC
Top line results from on-going pivotal efficacy laboratory classroom study of KP415
Attention-Deficit/Hyperactivity Disorder in children
Mid 2018
Pulmatrix Inc.
Results from Phase 1/1b study of Pulmazole
Fungal infections for severe asthma and cystic fibrosis patients